乳癌液体切片检测设备市场－全球产业规模、份额、趋势、机会及预测（按产品、循环生物标记、应用、区域及竞争情况细分，2020-2030 年预测）

2024 年全球乳癌液体活检检测设备市场价值为 8.3536 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 17.20%。液体活检是乳癌诊断和治疗领域的宝贵资产。透过液体活检分析突变有助于根据患者肿瘤特定的基因变化来确定针对个别患者的标靶治疗方法。例如，对于转移性乳癌患者，筛检约 40% HR 阳性肿瘤中发现的 PIK3CA 突变有助于确定最有效的治疗途径。例如，根据美国癌症协会 (ASC) 2023 年报告，乳癌仍然是美国女性中最常见的癌症（不包括皮肤癌）。它占每年诊断出的所有女性癌症的30%。为了降低乳癌的发病率和死亡率，政府发布了政策并发布了法律来支持患者承担诊断和治疗的费用。此外，根据世界卫生组织2023年的报告，每年诊断出的乳癌病例超过230万例，是成年人中最常见的癌症。然而，约 80% 的乳癌相关死亡发生在中低收入国家。

主要市场驱动因素

癌症检测技术的进步

主要市场挑战

敏感性和特异性有限

主要市场趋势

与传统诊断的整合

目录

第 1 章：产品概述

第 2 章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球乳癌液体切片检测设备市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品分类（分析试剂盒、仪器）
  • 依循环生物标记（循环肿瘤DNA、循环肿瘤细胞、细胞外囊泡）
  • 按应用（癌症应用、非癌症应用）
  • 按地区
  • 按公司分类（2022 年）
• 产品市场图
  • 按奉献
  • 透过循环生物标誌物
  • 按应用
  • 按地区

第六章：北美乳癌液体切片检测设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第七章：欧洲乳癌液体切片检测设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第八章：亚太地区乳癌液体切片检测设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第九章：南美洲乳癌液体切片检测设备市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲乳癌液体切片检测设备市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

第 15 章：策略建议

第16章调查会社について・免责事项

Global Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 835.36 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 17.20% through 2030. Liquid biopsy serves as a valuable asset in the realm of breast cancer diagnosis and treatment. The analysis of mutations through liquid biopsy aids in the identification of targeted therapies tailored to individual patients based on their tumor-specific genetic alterations. To illustrate, in the case of patients grappling with metastatic breast cancer, screening for the PIK3CA mutation, which is found in around 40% of HR-positive tumors, assists in determining the most effective treatment path. For instance, according to the American Society of Cancer (ASC) Report 2023, breast cancer remains the most common cancer among women in the United States, excluding skin cancers. It accounts for 30% of all female cancers diagnosed annually. In an effort to reduce the prevalence and mortality rates of breast cancer, the government has implemented policies and introduced laws to support patients with the costs of diagnosis and treatment. Also, according to the World Health Organization 2023 report, more than 2.3 million cases of breast cancer are diagnosed annually, making it the most prevalent cancer among adults. However, approximately 80% of breast cancer-related deaths occur in low- and middle-income countries.

Key Market Drivers

Advancements in Cancer Detection Technology

The landscape of cancer detection and diagnosis is evolving rapidly, and one area of remarkable progress is the development of liquid biopsy testing devices. These devices, which have gained prominence in the healthcare industry, are offering a non-invasive, highly sensitive, and patient-friendly approach to detect and monitor cancer, with breast cancer being a significant focus.

One of the keyways advancements in cancer detection technology are boosting the growth of the global breast cancer liquid biopsy market is by enhancing sensitivity and specificity. Liquid biopsies can now detect minute traces of circulating tumor DNA (ctDNA) or other biomarkers in a patient's bloodstream. This increased sensitivity ensures that even small tumors or minimal residual disease (MRD) can be detected accurately, which was often challenging with traditional diagnostic methods.

Key Market Challenges

Limited Sensitivity and Specificity

While liquid biopsy testing devices have advanced considerably, they may still face challenges related to sensitivity and specificity. Detecting circulating tumor DNA (ctDNA) or other biomarkers in the bloodstream can be challenging, especially for small or early-stage tumors. Improving the sensitivity and specificity of these tests remains a priority for the industry.

Key Market Trends

Integration with Conventional Diagnostics

The trend is moving towards the integration of liquid biopsy testing devices with traditional diagnostic methods. Combining liquid biopsies with imaging and tissue biopsies can provide a more comprehensive understanding of the disease. This integrated approach offers greater diagnostic accuracy and opens up new avenues for treatment decisions.

Key Market Players

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

Report Scope:

In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Liquid Biopsy Testing Devices Market, By Offerings:

• Assay & Reagents Kits
• Instruments

Breast Cancer Liquid Biopsy Testing Devices Market, By Circulating Biomarker:

• Circulating Tumor DNA
• Circulating Tumor Cell
• Extracellular Vesicles

Breast Cancer Liquid Biopsy Testing Devices Market, By Application:

• Cancer Applications
• Non-Cancer Applications

Breast Cancer Liquid Biopsy Testing Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Liquid Biopsy Testing Devices Market.

Available Customizations:

Global Breast Cancer Liquid Biopsy Testing Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 5.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 5.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Offerings
  • 5.3.2. By Circulating Biomarker
  • 5.3.3. By Application
  • 5.3.4. By Region

6. North America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 6.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 6.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offerings
      • 6.3.1.2.2. By Circulating Biomarker
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offerings
      • 6.3.2.2.2. By Circulating Biomarker
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offerings
      • 6.3.3.2.2. By Circulating Biomarker
      • 6.3.3.2.3. By Application

7. Europe Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 7.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 7.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offerings
      • 7.3.1.2.2. By Circulating Biomarker
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offerings
      • 7.3.2.2.2. By Circulating Biomarker
      • 7.3.2.2.3. By Application
  • 7.3.3. France Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offerings
      • 7.3.3.2.2. By Circulating Biomarker
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offerings
      • 7.3.4.2.2. By Circulating Biomarker
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offerings
      • 7.3.5.2.2. By Circulating Biomarker
      • 7.3.5.2.3. By Application

8. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 8.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 8.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offerings
      • 8.3.1.2.2. By Circulating Biomarker
      • 8.3.1.2.3. By Application
  • 8.3.2. Japan Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offerings
      • 8.3.2.2.2. By Circulating Biomarker
      • 8.3.2.2.3. By Application
  • 8.3.3. India Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offerings
      • 8.3.3.2.2. By Circulating Biomarker
      • 8.3.3.2.3. By Application
  • 8.3.4. Australia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offerings
      • 8.3.4.2.2. By Circulating Biomarker
      • 8.3.4.2.3. By Application
  • 8.3.5. South Korea Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offerings
      • 8.3.5.2.2. By Circulating Biomarker
      • 8.3.5.2.3. By Application

9. South America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 9.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 9.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offerings
      • 9.3.1.2.2. By Circulating Biomarker
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offerings
      • 9.3.2.2.2. By Circulating Biomarker
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offerings
      • 9.3.3.2.2. By Circulating Biomarker
      • 9.3.3.2.3. By Application

10. Middle East and Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 10.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 10.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offerings
      • 10.3.1.2.2. By Circulating Biomarker
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offerings
      • 10.3.2.2.2. By Circulating Biomarker
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offerings
      • 10.3.3.2.2. By Circulating Biomarker
      • 10.3.3.2.3. By Application
  • 10.3.4. Kuwait Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Offerings
      • 10.3.4.2.2. By Circulating Biomarker
      • 10.3.4.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. A Menarini AG
• 14.2. NeoGenomics Laboratories Inc
• 14.3. F Hoffmann-La Roche AG
• 14.4. Myriad Genetics Inc
• 14.5. QIAGEN NV
• 14.6. Biocept Inc
• 14.7. Sysmex Corp
• 14.8. Fluxion Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10. Epic Sciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer